🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In adults with #obesity studied in the real world TriNetX database, tirzepatide demonstrated superior clinical outcomes compared with metabolic surgery including significant reductions in all-cause mortality, MACEs and MAKEs dom-pubs.onlinelibrary.wiley.com/doi/full/10.11…

📢 Tirzepatide rollout for obesity: NHS starts phased access from June 2025 🔹 Specialist centres go live Mar 2025 (90-day mandate) 🔸 Primary care begins June 2025 (180-day mandate) 🔹 Cohort I: BMI ≥40 + ≥4 comorbidities (e.g. #T2D, CVD, OSA) 🔸 ~220K to access in 3 yrs;

#Denosumab withdrawal increases vertebral fracture and mortality risk compared with #zoledronate by Ko-Hsiu Lu et al EJE Volume 192, Issue 3, March 2025 Full paper 👉doi.org/10.1093/ejendo… ESE Members free access via 👉 my.ese-hormones.org #endocrinology #TriNetX

Anti-myostatin muscle-growing antibody #apitegromab has been submitted to the FDA for approval. nature.com/articles/d4157…

The new #DiabetesAtlas, launched today at #IDF2025 reveals that 589 million adults worldwide are living with diabetes — nearly 1 in 9. This number is expected to reach 853 million by 2050. Discover the lates global, regional and national data. 📊 diabetesatlas.org

In a 36,000 patient observational study, we found no increase in NAION, vision loss and papilledema with GLP1 RA use pubmed.ncbi.nlm.nih.gov/40196964/

Overview of clinical evidence for sex-specific effects of GLP-1 analogs and their potential interaction with estrogens. GLP-1 analogs are reshaping diabetes and obesity care, but sex differences in their effects are emerging. Women may experience distinct benefits and side

*New* 2025 JCS/JHFS Japanese Guidelines Prevention of #HF #SGLT2i class I (4 T2D & 4 CKD RCTs) #nsMRA class I (FIDELIO FIGARO) Treatment of #HFpEF #SGLT2i class I (DELIVER EMPEROR SOLOIST) #nsMRA class IIa (FINEARTS) #sMRA class IIb (TOPCAT) #ARNI/#ARB class IIb (PARAGON/CHARM)

The UK government is promoting a “strategic shift” from “treatment to prevention.” This requires action on wider determinants of health, say Vageesh Jain and Thomas Beaney bmj.com/content/389/bm…

Summary of changes in ghrelin, cholecystokinin, peptide tyrosine-tyrosine, and glucagon-like peptide-1 response to feeding across the life course, from infancy to later life. academic.oup.com/jes/article/9/…

A novel diagnostic score for diagnosing arginine vasopressin deficiency (central #diabetes #insipidus) or primary #polydipsia w/ basal laboratory & clinical parameters: results from two international multicentre prospective diagnostic studies thelancet.com/journals/landi… #OpenAccess

Patients are complaining they are struggling to get appointments with GPs which is leading to delays in their care. Newly qualified GPs are struggling to find regular work in NHS general practices. Surely there is a solution that will solve both these problems?

We sometimes hear that doctors “need to work at the top of licence” meaning they should do work that other staff cannot do. But how can doctors do this when in many hospitals and health centres they lack administrative support, office space and appropriate IT facilities?

For doctors, the ability to accept some clinical risk is important in their professional role. Experienced clinicians are more aware of the appropriate level of risk to accept. Less experienced clinicians will often follow guidelines rigidly or practise in a very risk averse way.

NO new Levemir starts advised - guidance on switching to follow ABCD Diabetes Young Diabetologists and Endocrinologists’ Forum Diabetes Technology Network UK DTN-UK PCDN Trend Diabetes

Urea-stimulated copeptin: a novel diagnostic approach in polyuria polydipsia syndrome by Sven Lustenberger et al EJE Volume 192, Issue 4, April 2025 Open access 👉 doi.org/10.1093/ejendo… #endocrinology #vasopressin #pituitary #diabetesinsipidus #AVPdeficiency

We’re proud to unveil positive topline results from our Ph2b IMPACT trial in #MASH, which position pemvidutide as the first product candidate to demonstrate significant MASH effects + #weightloss at just 24 weeks. Learn more here ir.altimmune.com/news-releases/…

Our UK Non-functioning Pituitary Adenoma Consortium papers in this guideline Conservatively managed non-functioning pituitary macroadenomas doi.org/10.1093/ejendo… Natural history of non-functioning pituitary microadenomas doi.org/10.1093/ejendo…

💉 GLP-1 meds don’t just curb appetite—sometimes they curb essential nutrients too. - - - 📉 In a study of 460,000+ adults on GLP-1s (mostly with T2D): 🔹13% developed nutritional deficiencies in 6 months 🔹22% within 12 months 🔹Vitamin D deficiency was most common (13.6%) 🔹3%